Agile Therapeutics (NASDAQ: AGRX)
Some price data may be temporarily unavailable.
Agile Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Agile Therapeutics Company Info
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
News & Analysis
Why Shares of Agile Therapeutics Jumped This Week
The women's healthcare company got an analyst upgrade.
Agile Therapeutics' Q3 Focused on Launching Its New Contraceptive Patch
The drugmaker will soon give Twirla a twirl.
Why Agile Therapeutics Stock Is Jumping Today
Agile's shares are heating up ahead of the company's Q1 earnings report.
Why Agile Therapeutics Stock Is Crashing Today
The biotech stock is getting hit hard by the marketwide downturn today. Here's why.
Why Agile Therapeutics Stock Is Getting Crushed Today
Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.
Why Agile Therapeutics Stock Is Falling Today
Shares drop after the company releases the pricing details of a recently announced capital raise.
Is Agile Therapeutics Stock a Buy After Its Big FDA Win?
Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.
Why Agile Therapeutics Stock Jumped Today
The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.